Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) CMO Joanne M. Donovan sold 7,162 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $28.29, for a total value of $202,612.98. Following the completion of the sale, the chief marketing officer now directly owns 14,538 shares of the company’s stock, valued at approximately $411,280.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Edgewise Therapeutics Stock Down 2.2 %
Shares of EWTX traded down $0.57 during trading on Tuesday, reaching $25.92. 988,944 shares of the company traded hands, compared to its average volume of 961,431. The stock has a 50-day simple moving average of $19.06 and a 200-day simple moving average of $18.20. The stock has a market cap of $2.42 billion, a PE ratio of -16.72 and a beta of 0.15. Edgewise Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $30.00.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. On average, equities research analysts predict that Edgewise Therapeutics, Inc. will post -1.48 EPS for the current year.
Hedge Funds Weigh In On Edgewise Therapeutics
Wall Street Analyst Weigh In
Several brokerages have issued reports on EWTX. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Edgewise Therapeutics in a report on Friday, August 16th. Piper Sandler reissued an “overweight” rating and issued a $48.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 1st. Truist Financial lifted their target price on shares of Edgewise Therapeutics from $25.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $32.00 price target on shares of Edgewise Therapeutics in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. raised their price target on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, August 12th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $35.00.
View Our Latest Stock Report on EWTX
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Featured Stories
- Five stocks we like better than Edgewise Therapeutics
- How to Use Stock Screeners to Find Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Financial Services Stocks Investing
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Most Volatile Stocks, What Investors Need to Know
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.